{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during treatment\n\n* Complete Response(CR): Complete disappearance of M-protein from serum \\& urine on immunofixation, normalization of Free Light Chain (FLC) ratio \\& \\<5% plasma cells in bone marrow (BM)\n* Very Good Partial Response(VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<100 mg per 24 hours; \\<=5% plasma cells in BM\n* Partial Response PR): \\>= 50% reduction in serum M-Component and/or Urine M-Component \\>= 90% reduction or \\<200 mg per 24 hours; or \\>= 50% decrease in difference between involved and uninvolved FLC levels","groups":[{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG000","title":"LCD (Cyclophosphamide 300 mg/m^2)"},{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"OG001","title":"LCD (Cyclophosphamide 300 mg)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of Treatment (up to 5 years)","title":"Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment","type":"PRIMARY","unitOfMeasure":"participants"}